These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Regulatory aspects of drug approval for macular degeneration. Gryziewicz L Adv Drug Deliv Rev; 2005 Dec; 57(14):2092-8. PubMed ID: 16316706 [TBL] [Abstract][Full Text] [Related]
28. Progressive visual loss in subfoveal exudation in age-related macular degeneration: a meta-analysis using Lineweaver-Burke plots. Shah AR; Del Priore LV Am J Ophthalmol; 2007 Jan; 143(1):83-89. PubMed ID: 17188044 [TBL] [Abstract][Full Text] [Related]
29. Posterior juxtascleral injection of anecortave acetate: magnetic resonance and echographic imaging and localization in rabbit eyes. Jockovich ME; Murray TG; Clifford PD; Moshfeghi AA Retina; 2007 Feb; 27(2):247-52. PubMed ID: 17290209 [TBL] [Abstract][Full Text] [Related]
30. Pegaptanib sodium for the treatment of neovascular age-related macular degeneration. Moshfeghi AA; Puliafito CA Expert Opin Investig Drugs; 2005 May; 14(5):671-82. PubMed ID: 15926872 [TBL] [Abstract][Full Text] [Related]
31. The Digital Angiography Reading Center (DARC) role in the anecortave acetate clinical trials. Slakter JS; Carvalho C; Coleman H Surv Ophthalmol; 2007 Jan; 52 Suppl 1():S91-8. PubMed ID: 17240261 [TBL] [Abstract][Full Text] [Related]
32. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation. Robin AL; Clark AF; Covert DW; Krueger S; Bergamini MV; Landry TA; Dickerson JE; Scheib SA; Realini T; Defaller JM; Cagle GD Am J Ophthalmol; 2009 Jan; 147(1):45-50.e2. PubMed ID: 18789793 [TBL] [Abstract][Full Text] [Related]
33. Emerging therapies for neovascular age-related macular degeneration: state of the art. Donati G Ophthalmologica; 2007; 221(6):366-77. PubMed ID: 17947822 [TBL] [Abstract][Full Text] [Related]
35. Identification of PDE6D as a molecular target of anecortave acetate via a methotrexate-anchored yeast three-hybrid screen. Shepard AR; Conrow RE; Pang IH; Jacobson N; Rezwan M; Rutschmann K; Auerbach D; Sriramaratnam R; Cornish VW ACS Chem Biol; 2013 Mar; 8(3):549-58. PubMed ID: 23301619 [TBL] [Abstract][Full Text] [Related]
36. [Is there a drug therapy for age-related macular degeneration?--current status and new therapeutic approaches]. Augustin AJ; Offermann I Klin Monbl Augenheilkd; 2008 Jun; 225(6):555-63. PubMed ID: 18516776 [TBL] [Abstract][Full Text] [Related]
37. Suppression of corticosteroid-induced ocular hypertension in sheep by anecortave. Candia OA; Gerometta R; Millar JC; Podos SM Arch Ophthalmol; 2010 Mar; 128(3):338-43. PubMed ID: 20212205 [TBL] [Abstract][Full Text] [Related]
38. Anecortave acetate as single and adjuvant therapy in the treatment of retinal tumors of LH(BETA)T(AG) mice. Jockovich ME; Murray TG; Escalona-Benz E; Hernandez E; Feuer W Invest Ophthalmol Vis Sci; 2006 Apr; 47(4):1264-8. PubMed ID: 16565356 [TBL] [Abstract][Full Text] [Related]
39. [Present status of studies on the treatment of choroidal neovascularization by Anecortave acetate]. Li X; Wang YS Zhonghua Yan Ke Za Zhi; 2008 Jun; 44(6):571-4. PubMed ID: 19035252 [TBL] [Abstract][Full Text] [Related]
40. Anecortave acetate for the treatment of idiopathic perifoveal telangiectasia: a pilot study. Eandi CM; Ober MD; Freund KB; Klais CM; Slakter JS; Sorenson JA; Yannuzzi LA Retina; 2006 Sep; 26(7):780-5. PubMed ID: 16963851 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]